Adaptive Biotechnologies
ADPT
242 hedge funds and large institutions have $1.73B invested in Adaptive Biotechnologies in 2025 Q2 according to their latest regulatory filings, with 46 funds opening new positions, 92 increasing their positions, 63 reducing their positions, and 26 closing their positions.
645% more call options, than puts
Call options by funds: $2.39M | Put options by funds: $321K
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
77% more first-time investments, than exits
New positions opened: 46 | Existing positions closed: 26
52% more capital invested
Capital invested by funds: $1.14B → $1.73B (+$590M)
46% more repeat investments, than reductions
Existing positions increased: 92 | Existing positions reduced: 63
8% more funds holding
Funds holding: 225 → 242 (+17)
5.39% less ownership
Funds ownership: 102.92% → 97.52% (-5.4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FAM
Fred Alger Management
New York
|
+$21.4M |
| 2 |
BlackRock
New York
|
+$13.1M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$12.5M |
| 4 |
CCM
Catalio Capital Management
New York
|
+$7.13M |
| 5 |
First Trust Advisors
Wheaton,
Illinois
|
+$6.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$62.3M |
| 2 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$33.8M |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
-$30.9M |
| 4 |
Millennium Management
New York
|
-$18M |
| 5 |
NAMA
Nikko Asset Management Americas
New York
|
-$16.2M |
ADPT Hedge Fund Activity: Q2 2025 in Review
242 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Adaptive Biotechnologies (ADPT) for Q2 2025, worth a combined $1.73B — up 52% from $1.14B a quarter earlier.
Buyers outnumbered sellers: 46 funds opened new ADPT positions and 26 closed out — a net gain of 20 holders — while 92 added to existing stakes and 63 trimmed.
The largest buyer was Fred Alger Management, opening a new position worth an estimated $21.4M. The largest seller was Rubric Capital Management (New York), cutting an estimated $62.3M.
- 242 institutional investors held Adaptive Biotechnologies (ADPT) as of Q2 2025, up from 225 in Q1 2025.
- Funds reported $1.73B of Adaptive Biotechnologies stock for Q2 2025, up 52% quarter-over-quarter.
- 46 funds opened new Adaptive Biotechnologies positions in Q2 2025 and 26 closed out, a net change of +20 holders.
- The largest Adaptive Biotechnologies buyer in Q2 2025 was Fred Alger Management, an estimated $21.4M added.
- The largest Adaptive Biotechnologies seller in Q2 2025 was Rubric Capital Management (New York), an estimated $62.3M sold.
Based on aggregated 13F filings for Q2 2025.